Clinical Trial Update: A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals [Phase 1]

View source ↗

Summary

Phase 1 randomized, double-blind, placebo-controlled study evaluating safety, tolerability, and immunogenicity of HIV-1 vaccines ChAdOx1.HTI and MVA.HTI with th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ChAdOx1.HTI
• ConM SOSIP.v7 gp140 (HIV-1 envelope protein ConM SOSIP.v7 gp140)
• MPLA liposome adjuvant (Monophosphoryl lipid A liposome adjuvant)
• MVA.HTI

Snippet

Sponsor: IrsiCaixa | Conditions: HIV Infection | Phase 1 | Status: COMPLETED